2011
DOI: 10.1016/j.ejca.2010.10.024
|View full text |Cite
|
Sign up to set email alerts
|

Glypican-3: A new target for cancer immunotherapy

Abstract: Hepatocellular carcinoma (HCC) remains a common malignant cancer worldwide. There is an urgent need to identify new molecular targets for the development of novel therapeutic approaches. Here, we review the structure, function and biology of Glypican-3 (GPC3) and its role in human cancer with a focus on its potential as a therapeutic target for immunotherapy. GPC3 is a cell-surface protein that is over-expressed in HCC. Loss-of-function mutations of GPC3 cause Simpson-Golabi-Behmel syndrome, a rare X-linked ov… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

6
190
1
1

Year Published

2012
2012
2023
2023

Publication Types

Select...
4
1
1

Relationship

0
6

Authors

Journals

citations
Cited by 194 publications
(198 citation statements)
references
References 51 publications
6
190
1
1
Order By: Relevance
“…Glypican-3 is a cell surface protein [1] that is involved in the control of cell proliferation and survival. Glypican-3-knockout mice exhibit alterations in Wnt signalling [45].…”
Section: Hepatocellular Carcinomamentioning
confidence: 99%
See 4 more Smart Citations
“…Glypican-3 is a cell surface protein [1] that is involved in the control of cell proliferation and survival. Glypican-3-knockout mice exhibit alterations in Wnt signalling [45].…”
Section: Hepatocellular Carcinomamentioning
confidence: 99%
“…In addition, 10% of gastric cancer cases are positive for glypican-3 [55]. In melanoma, 80% of tumours contain detectable level of glypican-3 protein and mRNA [1]. Regarding ovarian cancer, the rate of glypican expression could be as high as 18% of all ovarian cancer cases and 60% of clear cell carcinoma cases [51].…”
Section: Hepatocellular Carcinomamentioning
confidence: 99%
See 3 more Smart Citations